Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $123.6 million.

  • Kiniksa Pharmaceuticals International's Total Current Liabilities rose 2880.2% to $123.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.6 million, marking a year-over-year increase of 2880.2%. This contributed to the annual value of $100.6 million for FY2024, which is 5804.51% up from last year.
  • Kiniksa Pharmaceuticals International's Total Current Liabilities amounted to $123.6 million in Q3 2025, which was up 2880.2% from $117.8 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Total Current Liabilities high stood at $123.6 million for Q3 2025, and its period low was $34.4 million during Q3 2021.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Total Current Liabilities had a median value of $53.5 million in 2023 and averaged $65.0 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Total Current Liabilities crashed by 2734.04% in 2023 and then surged by 7946.25% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Total Current Liabilities (Quarter) stood at $44.8 million in 2021, then increased by 5.0% to $47.1 million in 2022, then soared by 35.27% to $63.7 million in 2023, then soared by 58.05% to $100.6 million in 2024, then grew by 22.83% to $123.6 million in 2025.
  • Its Total Current Liabilities was $123.6 million in Q3 2025, compared to $117.8 million in Q2 2025 and $97.3 million in Q1 2025.